NCT00072137终止1 期
Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 21
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose (MTD) assessed by Common Toxicity Criteria (CTC)
研究概览
简要总结
This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving a vaccine directly into the bladder before surgery may cause a stronger immune response and keep tumor cells from coming back after surgery.
详细描述
PRIMARY OBJECTIVES:
I. To assess the safety of intravesical administration of recombinant fowlpox virus encoding three different costimulatory molecules (B7.1, ICAM-1,LFA-3) called TRICOM (-rF-TRICOM) (recombinant fowlpox-TRICOM vaccine) and/or recombinant fowlpox encoding sargramostim (GM-CSF) (rF-GM-CSF) (recombinant fowlpox GM-CSF vaccine adjuvant) in the treatment of patients with carcinoma of the bladder scheduled for cystectomy.
SECONDARY OBJECTIVES:
I. Determine the kinetics of viral infection and gene function as well as host response to intravesical recombinant fowlpox virus in the treatment of bladder cancer.
OUTLINE: This is a dose-escalation study. Patients are alternately assigned to Arms A and B. Once Arms A and B have finished accrual, patients are assigned to Arm C.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a histologically documented bladder cancer including: transitional cell carcinoma, adenocarcinoma, or squamous cell carcinoma including carcinoma in situ (CIS) requiring cystectomy as a standard therapy for his/her tumor stage and be scheduled for this surgical procedure; patients should not be candidates for neoadjuvant chemotherapy
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Estimated life expectancy 6 or more months
- •Prior therapy with intravesical Bacille Calmette-Guerin (BCG) and/or chemotherapy is allowed; patient must be at least 2 months beyond the instillation of any prior intravesical agent; patients should not have received systemic chemotherapy, radiation therapy, immunotherapy or systemic doses of steroids for at least 4 weeks prior to starting vaccination and have recovered from all acute toxicities of previous treatment; patients who have received neoadjuvant chemotherapy or radiation therapy to the bladder will be ineligible for this study
- •Serum creatinine < 1.5 mg/dl or a creatinine clearance > 60 ml/min
- •Bilirubin < 2.0 mg/dl
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 x normal range
- •Absolute neutrophil count (ANC) > 1500/mm^3
- •Platelets > 75000/mm^3
- •Patients must not have known immunodeficiency disorder (acquired immunodeficiency syndrome [AIDS], severe combined immunodeficiency [SCID], Wiskott-Aldrich syndrome, etc.); study candidates will not be specifically screened for these, unless clinically indicated; if indicated, the referring physician will do the evaluation
- •No active/uncontrolled infections
- •Pregnant women or nursing mothers are ineligible; women with reproductive potential must have negative pregnancy test and are prohibited from sexual intercourse during this study (while receiving vaccine and at least 1 month following last dose); sexual abstinence (as opposed to contraception only) is necessary; similarly, male patients also must avoid sex for the same period as above
- •No uncontrolled psychiatric illness or medical illness that the principal investigator feels will compromise the patient's tolerance of the study treatment
- •Patients must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines; patients who cannot provide informed consent will not be eligible for the study
排除标准
- •Altered immune-competence:
- •Current or imminent steroid therapy or active antibiotic therapy (antibiotics given for prophylaxis are allowed)
- •Immune deficiency disease or immunosuppressive therapy in the patient
- •Present or history of an autoimmune disease in the patient (e.g. autoimmune neutropenia, thrombocytopenia, or hemolytic anemia; systemic lupus erythematosus, Sjogren syndrome, or scleroderma; myasthenia gravis; Goodpasture syndrome; Addison's disease, Hashimoto's thyroiditis, active Graves' disease, or other diseases which qualify as autoimmune in origin)
- •History of allergy to eggs as this vaccine is manufactured in chicken embryo cells
- •Patients with any presence of liver function abnormalities, exposure to toxins, ongoing alcohol consumption, history of liver disease and/or history of hepatitis that may suggest persistent disease
- •Any concurrent active second malignancy or any malignant tumor within the prior 5 years with the exception of a superficial squamous or basal cell skin carcinoma or in situ carcinoma of the cervix or prostate
- •Pregnancy
- •Patients with active ischemic heart disease (i.e. class III or IV cardiac disease-New York Heart Association), a recent history of myocardial infarction (within the last 6 months), history of congestive heart failure, ventricular arrhythmias or other arrhythmias requiring therapy
结局指标
主要结局
Maximum tolerated dose (MTD) assessed by Common Toxicity Criteria (CTC)
时间窗: Up to 39 days
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerAdenocarcinoma of the ColonAdenocarcinoma of the GallbladderAdenocarcinoma of the PancreasAdenocarcinoma of the RectumAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the GallbladderDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachOvarian Endometrioid AdenocarcinomaPaget Disease of the Breast With Intraductal CarcinomaPaget Disease of the Breast With Invasive Ductal CarcinomaRecurrent Adult Primary Liver CancerRecurrent Breast CancerRecurrent Colon CancerRecurrent Gallbladder CancerRecurrent Gastric CancerRecurrent Malignant Testicular Germ Cell TumorRecurrent Pancreatic CancerRecurrent Rectal CancerRecurrent Salivary Gland CancerSalivary Gland AdenocarcinomaStage II Malignant Testicular Germ Cell TumorStage II Pancreatic CancerStage III Colon CancerStage III Gastric CancerStage III Malignant Testicular Germ Cell TumorStage III Pancreatic CancerStage III Rectal CancerStage III Salivary Gland CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IV Breast CancerStage IV Colon CancerStage IV Gastric CancerStage IV Pancreatic CancerStage IV Rectal CancerStage IV Salivary Gland CancerThyroid Gland Medullary CarcinomaUnresectable Gallbladder CancerMale Breast CancerNCT00028496National Cancer Institute (NCI)48
终止
2 期
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate CancerNCT00005039National Cancer Institute (NCI)86
已完成
1 期
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid TumorsAdvanced Malignant Solid NeoplasmHepatocellular CarcinomaNCT01628640Mayo Clinic17
已完成
1 期
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by SurgeryMetastatic Malignant Peripheral Nerve Sheath TumorNeurofibromatosis Type 1Recurrent Malignant Peripheral Nerve Sheath TumorNCT02700230Mayo Clinic30
已完成
1 期
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast CancerEstrogen Receptor NegativeEstrogen Receptor PositiveHead and Neck Squamous Cell CarcinomaHER2/Neu NegativeHER2/Neu PositiveInvasive Breast CarcinomaProgesterone Receptor NegativeProgesterone Receptor PositiveRecurrent Head and Neck CarcinomaStage IV Breast CancerTriple-Negative Breast CarcinomaNCT01846091Mayo Clinic12